- Home
- CANF vs FGI Comparison
CANF vs FGI Comparison
Compare CANF & FGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- FGI
- Stock Information
- Founded
- CANF 1994
- FGI 1987
- Country
- CANF Israel
- FGI United States
- Employees
- CANF N/A
- FGI N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- FGI Industrial Specialties
- Sector
- CANF Health Care
- FGI Industrials
- Exchange
- CANF Nasdaq
- FGI Nasdaq
- Market Cap
- CANF 9.4M
- FGI 8.0M
- IPO Year
- CANF N/A
- FGI 2022
- Fundamental
- Price
- CANF $1.81
- FGI $0.86
- Analyst Decision
- CANF Strong Buy
- FGI
- Analyst Count
- CANF 2
- FGI 0
- Target Price
- CANF $14.00
- FGI N/A
- AVG Volume (30 Days)
- CANF 122.9K
- FGI 5.4K
- Earning Date
- CANF 03-04-2025
- FGI 03-19-2025
- Dividend Yield
- CANF N/A
- FGI N/A
- EPS Growth
- CANF N/A
- FGI N/A
- EPS
- CANF N/A
- FGI N/A
- Revenue
- CANF $667,000.00
- FGI $127,180,460.00
- Revenue This Year
- CANF $409.56
- FGI $11.39
- Revenue Next Year
- CANF N/A
- FGI $6.26
- P/E Ratio
- CANF N/A
- FGI N/A
- Revenue Growth
- CANF N/A
- FGI 7.71
- 52 Week Low
- CANF $1.29
- FGI $0.70
- 52 Week High
- CANF $4.69
- FGI $1.85
- Technical
- Relative Strength Index (RSI)
- CANF 64.57
- FGI 52.15
- Support Level
- CANF $1.45
- FGI $0.81
- Resistance Level
- CANF $1.50
- FGI $0.87
- Average True Range (ATR)
- CANF 0.12
- FGI 0.04
- MACD
- CANF 0.05
- FGI -0.00
- Stochastic Oscillator
- CANF 66.67
- FGI 61.20
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. It offers sanitaryware, bath furniture, shower systems, customer kitchen cabinetry, and other accessory items. It is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. its revenue is generated by sanitaryware. Geographically it operates in the United States, Canada, Europe, Rest of the World, and the majority of its revenue comes from the United States.